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We have reported on a novel adenovirus serotype 5 (Ad5)
vector gene delivery platform (Ad5 [E1-, E2b-]), in which
regions of the early 1 (E1), early 2 (E2b), and early 3 (E3)
genes have been deleted. The unique deletions in this plat-
form result in a dramatic decrease in late gene expression,
leading to a marked reduction in host immune response
to the vector. CEA, MUC1, and brachyury are tumor-asso-
ciated antigens (TAA) expressed on a wide range of
human tumors. Ad5 [E1-, E2b-]–CEA vaccine (ETBX-
011) has been employed in clinical studies as an active vac-
cine to induce immune responses to CEA in metastatic
colorectal cancer patients. The Ad5 [E1-, E2b-]–CEA vec-
tor encodes the entire CEA sequence modified to express
an enhancer T-cell epitope. We report here the develop-
ment of novel Ad5 [E1-, E2b-]–brachyury and Ad5 [E1-,
E2b-]–MUC-1 vaccine constructs. The Ad5 [E1-, E2b-]–
brachyury vector was constructed to encode the entire
brachyury gene devoid of 25 amino acids involved in DNA
binding, and modified to express an enhancer T cell epi-
tope. The Ad5 [E1-, E2b-]–MUC-1 vector was constructed
to encode the entire MUC-1 transgene with eight agonist
epitopes, including five in the C-terminus. Our results
show that these constructs (CEA, MUC1 and brachyury)
are capable of activation, as well as generation of antigen
specific T cells in vitro, and of inducing antigen-specific T
cells in vaccinated mice. We have also demonstrated that
the use of a combination of the three vaccines (designated
Tri-Ad5) displays little, if any, antigenic competition in in
vitro studies of human dendritic cells for antigen-specific
T cell activation and generation, or in murine vaccination
studies. The studies reported here support the rationale
for the application of Tri-Ad5 as a therapeutic modality to
induce immune responses to a diverse range of human
TAAs for potential clinical studies.
Authors’ details
1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2Etubics Corporation, Seattle, WA, USA. 3Laboratory of Tumor Immunology
and Biology, Center for Cancer Research, National Cancer Institute, National
Institutes of Health, Bethesda, MD, USA. 4Genitourinary Malignancies Branch,
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P452
Cite this article as: Tsang et al.: The generation and analysis of a novel
combination of recombinant adenovirus vaccines targeting three tumor
antigens as an immunotherapeutic. Journal for ImmunoTherapy of Cancer
2015 3(Suppl 2):P452.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article
Tsang et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P452
http://www.immunotherapyofcancer.org/content/3/S2/P452
© 2015 Tsang et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
